One Hotel Drive,

Boston,

Massachusetts,

US,

ZIP: 02128

Phone: (+1) 617 455 4188

There's significant momentum in the clinical and preclinical pipeline for dry AMD, backed by record-breaking investments and acquisitions. This was further demonstrated by the landmark first approval in February this year. The question for the field now is - what's next?

Uniting 100+ experts across biotech and pharma who are actively developing drugs that have the potential to revolutionize treatment of dry AMD, the 4th Annual Dry AMD Therapeutic Development Summit is back this November to answer that very question.

Find out more in the event guide - https://ter.li/gf8ab7

Dry AMD therapeutic development is the hottest topic in the ocular space right now. Join us to accelerate the drug pipeline and revolutionize dry AMD treatment for millions of patients in the US and worldwide.

Register to attend - https://ter.li/4mdotb


URL:
Brochure: https://go.evvnt.com/1854282-0?pid=1052

Prices:
Conference Only - Drug Developer: USD 2999.00,
Conference + 1 Workshop - Drug Developer: USD 3648.00,
Full Conference Access - Drug Developer: USD 4297.00,
Conference Only - Solution Provider: USD 3799.00,
Conference + 1 Workshop - Solution Provider: USD 4548.00,
Full Conference Access - Solution Provider: USD 5297.00,
Conference Only - Academic: USD 2599.00,
Conference + 1 Workshop - Academic: USD 3148.00,
Full Conference Access - Academic: USD 3697.00

Arun Upadhyay - Ocugen, Barbel (Barb) Rohrer - Medical University of South Carolina, Brian Culley - Lineage Cell Therapeutic, Christine Curcio - University of Alabama at Birmingham, Daniel Chao - Janssen Global Services, Daphna Mokady - Endogena Therapeutics, David Callanan - Aviceda Therapeutics, Donald Fong - Annexon Biosciences, Jane Lebkowski - Regenerative Patch Technologies, Jason Ehrlich - Kodiak Sciences, Jing Hua - Boehringer Ingelheim, Jogin Desai - Eyestem Research, John Edwards - Drusolv Therapeutics, Katie Binley - Ikarovec, Leonide Saad - Alkeus Pharmaceuticals, Luke Zack - IVERIC bio, Marty Emanuele - Visgenx, Melissa A. Calton - 4D Molecular Therapeutics, Michael Ehrlich - Alexion Pharmaceuticals, Paul Ashton - Inflammasome Therapeutics, Rachel Sartaj - Gyroscope Therapeutics, Reenie McCarthy - Stealth BioTherapeutics, Samarendra Mohanty - Nanoscope Technologies, Scott Borland - Annexon Biosciences, Shelley Boyd - Translatum Medicus, Stephen Poor - Novartis, Tea Soon Park - National Institute of Health Science, Vicken Karageozian - Allegro Ophthalmics, Wolfgang Klein - Katairo GmbH